Short Courses | Day 1 | Day 2 | Download Brochure
8:00 am Registration and Morning Coffee
8:30 Chairperson’s Opening Remarks
Stefan Dübel, Ph.D., Professor, Technical Institute of Braunsweig
8:35 Structure-Based Prediction of Antibody Epitopes
Julia Ponomarenko, Ph.D., Senior Scientist, Computational Biology, Skaggs School of Pharmacy & Pharmaceutical Science, San Diego Supercomputer Center, University of California, San Diego
Prediction of antibody epitopes, or antibody binding patches on the surface of protein antigens, remains challenging yet highly desirable for the design of vaccines and immunodiagnostics. In this work, we ask whether a comprehensive analysis of sequence and structural properties of three-dimensional structures of antibody-protein complexes enables reliable prediction of epitopes, or this task is still infeasible, given our current knowledge of protein antigenicity and antibody repertoire.
9:05 A Novel Approach to Antibody Drug Conjugates
James Prudent, Ph.D., CEO, Research & Development, Centrose LLC
Despite the potential of the antibody drug conjugate concept, a key complication in the development of effective ADCs exists: drug-antibody cell internalization followed by active drug separation. In order to circumvent this, we envisioned that a new class of ADCs where internalization and antibody-drug separation would not be required could be developed. Data will be presented that shows this concept is valid and may be broadly applicable.
Sponsored by
9:35 A Paradigm Shift in Protein Expression Enabling Lead Selection Concomitant with Isolation of the Production Cell Line
Andrew Sandford, B.Sc., Vice President, Selexis S.A.
From discovery to manufacturing, approaches to protein expression vary widely depending on the type of protein being expressed, application of use, amount required, project timeline and the preferences of the scientist conducting the research. This variability often necessitates expression system reformatting which can extend timelines, impact protein quality and compromise fundamental preclinical decision. Selexis SA has developed an uncomplicated and efficient approach allowing for the expression an identification of lead molecules while isolating the Production Cell Line.
10:05 Coffee Break, Poster and Exhibit Viewing
11:05 DARPins as Alternative to Antibodies
Michael T. Stumpp, Ph.D., CSO, Molecular Partners AG
DARPins are a novel class of high-affinity, low-immunogenicity protein drugs that combine the advantages of antibodies and small molecule drugs. The favorable properties of DARPins enable the fast generation and production of a variety of drug candidates for different indications. Examples of how to generate DARPins and select therapeutic drug candidates with superior characteristics will be discussed. A best-in-class therapeutic program, called MP0112, the lead DARPin to treat ocular neovascularization diseases, will be presented.
11:35 Fc N-linked Oligosaccharides and their Effect on Recombinant IgG1 Monoclonal Antibody Binding to Protein-A and Protein-G
Georgeen Gaza-Bulseco, M.S., Senior Research Scientist, Abbott Bioresearch Center
Effects of N-linked oligosaccharides in the Fc region of a recombinant IgG1 on the binding to Protein-A and Protein-G were investigated. Deglycosylated antibodies eluted later from Protein-A but earlier from Protein-G resins than glycosylated antibodies when a decreasing pH gradient was used. In addition, presence of different types of oligosaccharides affected elution of the antibodies. Antibody glycosylation status had no effect on antigen binding suggesting that differences in elution profiles were due to structural changes in the CH2-CH3 domain interface under low pH conditions.
12:05 pm End of Conference
Short Courses | Day 1 | Day 2 | Download Brochure
Program Navigation